Amgen (NASDAQ:AMGN) Announces Earnings Results, Beats Estimates By $0.53 EPS

Amgen (NASDAQ:AMGN) issued its quarterly earnings results on Tuesday. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53, FiscalAI reports. Amgen had a return on equity of 152.71% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen updated its FY 2026 guidance to 21.600-23.000 EPS.

Here are the key takeaways from Amgen’s conference call:

• Amgen reported double‑digit revenue and EPS growth in 2025, with 14 blockbusters and 18 record products, and provided 2026 guidance of $37.0B–$38.4B in revenue and $21.60–$23.00 non‑GAAP EPS, supported by $8.1B free cash flow and ongoing capital returns.
• MariTide is advancing rapidly with six global Phase 3 trials (weight management, T2D, sleep apnea, ASCVD, heart failure), fully enrolled chronic weight studies, and data supporting potential monthly or less‑frequent dosing that management calls “paradigm‑changing.”
• The Phase 3 VISSCELIA‑CV data for Repatha showed a 25% reduction in first major cardiovascular events and a 36% reduction in heart attack, strengthening its position for earlier use (primary prevention) and supporting commercial initiatives like Amgen Now to improve access.
• Biosimilars and oncology remain growth engines — the biosimilars franchise generated $3B in 2025 (>$13B since 2018) and the innovative oncology portfolio (including Imdelltra) grew 11% to $8.7B, with Imdelltra achieving full approval and rapid adoption in small cell lung cancer.
• The FDA requested a voluntary withdrawal of Tavneos following concerns about ChemoCentryx’s readjudication process for nine patients in the pivotal trial; Amgen is in discussions with the agency, creating regulatory uncertainty for that product.

Amgen Trading Up 8.2%

NASDAQ:AMGN opened at $366.22 on Thursday. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The stock has a fifty day moving average price of $333.19 and a two-hundred day moving average price of $310.44. The stock has a market capitalization of $197.20 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 2.98 and a beta of 0.46. Amgen has a 1 year low of $261.43 and a 1 year high of $368.75.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.8%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is presently 73.57%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Morgan Stanley raised their target price on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $347.65.

Insider Transactions at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 over the last ninety days. 0.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AMGN. Binnacle Investments Inc increased its position in shares of Amgen by 26.1% in the third quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock worth $59,000 after acquiring an additional 43 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Amgen by 435.8% in the third quarter. Caitong International Asset Management Co. Ltd now owns 284 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 231 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Amgen during the second quarter worth about $135,000. Florida Financial Advisors LLC purchased a new stake in shares of Amgen in the second quarter worth about $202,000. Finally, Abel Hall LLC acquired a new stake in shares of Amgen in the third quarter valued at about $222,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat consensus — Amgen reported $5.29 EPS vs. $4.76 expected and $9.87B revenue vs. $9.46B, driven by volume growth and a lower tax rate; management gave FY2026 EPS and revenue guidance that broadly supports growth. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
• Positive Sentiment: Obesity and pipeline catalysts in focus — Analysts and coverage highlight MariTide (obesity) and other label updates as potential upside to 2026 estimates, keeping investor attention on forward growth beyond legacy products. AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook
• Positive Sentiment: Momentum signal — Shares have pushed to 52-week highs and commentators note institutional demand and technical buy signals, which is amplifying buying pressure. Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
• Positive Sentiment: Analyst upgrades — Several firms raised price targets (Goldman to $415, RBC and Leerink higher), with Goldman maintaining a Buy — supporting near-term sentiment and investor confidence. Goldman Sachs adjusts price target on Amgen to $415 from $403, maintains buy rating
• Neutral Sentiment: Mixed analyst takeaways — While some shops raised targets, other analysts kept Hold/Equal-Weight calls; opinion is heterogeneous, so upside expectations vary across the sell-side. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Execution and regulatory risks — Commentators flag legacy product erosion, regulatory tension around Tavneos, and execution risk that could limit upside if pipeline or label wins are delayed. Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
• Negative Sentiment: Some price targets still imply limited upside — A few firms’ targets (e.g., Morgan Stanley, Cantor Fitzgerald’s neutral positioning at lower PTs) suggest room for profit-taking if momentum fades. Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.